



To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001

Date: 30.05.2023

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 30.05.2023

Unit: Decipher Labs Limited

With reference to the subject cited, this is to inform the Exchanges that the Board of Directors of **Decipher Labs Limited** at its meeting held on Tuesday, the 30th day of May, 2023 at 5.30 p.m. inter-alia considered and approved the following items of business:

1. Audited Financial Results (standalone and consolidated) for the Quarter and Financial year ended 31st March, 2023. (enclosed as Annexure).
2. Audit Report (standalone and consolidated) for the Quarter and year ended 31st March, 2023. (enclosed as Annexure).

The meeting concluded at 07:00 P.M. This is for the information and records of the Exchanges, please.

Thanking you.

Yours Faithfully

For Decipher Labs Limited

Megha Agarwal
Company Secretary and Compliance Officer

Encl. as above



Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of Decipher Labs Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of Decipher labs Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly financial results of Decipher Labs Limited (Formerly known as Combat Drugs Limited) (the Company) for the quarter ended 31st March, 2023 and the year-to-date results for the period from 1st April, 2022 to 31st March, 2023, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net loss and other comprehensive income and other financial information for the quarter ended 31st March, 2023 as well as the year-to-date results for the period from 1st April, 2022 to 31st March, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.



Management's Responsibilities for the Standalone Financial Results

These quarterly standalone financial results as well as the year-to-date financial results have been prepared on the basis of the standalone interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The standalone financial results include the results for the quarter ended 31st March, 2023 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)



K.Sreenivasan

Partner

Membership No.206421

UDIN: 23206421BGTHOY6359

Place : Secunderabad

Date : 30.05.2023





Independent Auditor's Report on the Quarterly and Year to Date Audited Consolidated Financial Results of Decipher Labs Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

**The Board of Directors of Decipher Labs Limited
Report on the Audit of Consolidated Financial Results**

Opinion

We have audited the accompanying consolidated annual financial results of Decipher Labs Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31st March, 2023, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements/financial results/financial information of the subsidiaries, the aforesaid consolidated financial results:

- i. include the annual financial results of the following entities
Decipher Software Solutions LLC, USA
Decipher Soft Middle East W.L.L Bahrain
- ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- iii. give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the Group for the year ended 31st March, 2023.



Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditor in terms of their report referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.



Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the holding company and subsidiary company incorporated in India have adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.



- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated financial results, which have been audited by other auditor, such other auditor remains responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

1. The consolidated financial results include the financial results of Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain whose financial statements/financial results/ financial information reflect total assets of Rs 2757.46 Lakhs as at 31st March, 2023, total revenue of Rs 964.57 lakhs and Rs 4476.27 lakhs, total net profit of Rs (390.36) lakhs and Rs (6.48) lakhs for the quarter ended 31st March, 2023 and for the period from 1st April, 2022 to 31st March, 2023 respectively, and net cash inflow of Rs (798.24) lakhs for the year ended 31st March, 2023. The independent auditors' reports on financial statements/financial results/ financial information of these entities has been furnished to us and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us are as stated in the paragraph above.

Our opinion on the consolidated financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial results/financial information certified by the Board of Directors.

The financial statements of subsidiaries, located outside India, have been prepared in accordance with accounting principles generally accepted in that country and which have been audited by other auditors under generally accepted auditing standards applicable in that



Ramanatham & Rao

Chartered Accountants

country. The Management has converted the financial statements of the subsidiaries located outside India from accounting principles generally accepted in that country to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries is based on the report of other auditors and the conversion adjustments prepared by the Management and audited by us. Our opinion is not modified in respect of this matter.

2. The consolidated Financial Results include the results for the quarter ended 31st March, 2023 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Ramanatham & Rao
Chartered Accountants
(Firm Regn.No.0029345)



K Sreenivasan

Partner

Membership No: 206421

UDIN: 232064218GTHPA1739

Place: Secunderabad

Date: 30.05.2023



DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society, BanjaraHills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, Mail: info@decipherlabs.in, Ph: 040-48536100

Standalone Statement of Assets and Liabilities

Rs. in Lakhs

Particulars	As at	As at
	31 March 2023	31 March 2022
	Audited	Audited
I. ASSETS		
Non-current assets		
(a) Property Plant and Equipment	11.87	33.46
(b) Financial assets		
Investments	866.41	866.41
(c) Other non-current assets	0.30	0.30
(d) Deferred Tax Assets	2.00	-
Current assets		
(a) Inventories	-	4.42
(b) Financial assets		
(i) Trade receivables	12.74	21.54
(ii) Cash and cash equivalents	5.62	4.76
(iii) Other financial assets	-	0.55
(c) Current tax assets	0.03	0.06
(d) Other current assets	-	228.85
TOTAL ASSETS	898.98	1,160.35
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	(119.57)	142.17
Liabilities		
Non-current liabilities		
(a) Deferred tax liabilities (net)	-	0.14
Current Liabilities		
(a) Financial liabilities		
(ii) Trade payables		
a) Total outstanding dues of Micro and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro and small enterprises	-	-
(iii) Other financial liabilities	7.73	7.00
(b) Other current liabilities	0.81	1.04
TOTAL EQUITY AND LIABILITIES	898.98	1,160.35



For and on behalf of the Board

Sushant Mohan Lal

Director

DIN: 01227151

Place: Hyderabad

Date: 30.05.2023

DECIPHER LABS LIMITED. (CIN CL23230TG1986PLC006781)

Regd. off: 4th Floor, Plot No. 94, Sagar Society Banjara Hills, Road No. 2, Hyderabad, Telangana, India - 500034
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Statement of Standalone Financial Results For the Quarter and Year Ended 31st March, 2023

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Year ended	
	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	12.94	2.93	24.46	81.00	98.84
II. Other income	0.38	0.60	3.23	2.82	4.59
III. Total Income (I + II)	13.32	3.53	27.69	83.82	66.97
IV. Expenses					
Purchase of Stock in trade	10.35	2.25	-	47.25	15.53
Changes in inventories of stock in trade	4.42	-	-	4.42	-
Employee Benefits Expense	7.46	4.36	4.46	20.11	23.32
Finance Costs	-	-	-	-	-
Depreciation expense	1.36	1.46	1.41	5.74	5.01
Other expenses	23.63	4.07	8.87	46.03	23.78
Total expenses	47.22	12.14	14.74	123.55	67.64
V. Profit before Exceptional items (III - IV)	(33.91)	(8.62)	12.95	(39.74)	35.79
VI. Exceptional items	0.00	224.15	-	224.15	-
VII. Profit after Exceptional items (V - VI)	(33.91)	(232.77)	12.95	(263.89)	35.79
VIII. Tax expense:					
(1) Current tax	-	-	-	-	-
(2) Deferred tax	(2.62)	(0.03)	(0.37)	(2.14)	(0.25)
IX. Profit/(Loss) for the period (VII-VIII)	(36.53)	(232.79)	13.32	(261.75)	36.04
X. Other comprehensive income					
XI. Total comprehensive income for the year	(36.53)	(232.79)	13.32	(261.75)	36.04
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share					
(1) Basic	(0.36)	(2.30)	0.13	(2.59)	0.36
(2) Diluted	(0.36)	(2.30)	0.13	(2.59)	0.36

Notes

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Year Ended	
	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
	Audited	Unaudited	Audited	Audited	Unaudited
Segment Revenue					
a) Manufacturing and Trading of Pharmaceutical drugs	12.94	2.92	30.02	64.96	68.82
b) Consultancy Services	(0.00)	-	7.43	16.04	30.02
Total Sales	12.94	2.92	24.46	81.00	98.84
Less: Inter Segment Revenue	-	-	-	-	-
Total Revenue from Operations	12.94	2.92	24.46	81.00	98.84
Segment Result (Profit Before Tax and Interest from each Segment)					
a) Manufacturing and Trading of Pharmaceutical drugs	(27.42)	(8.62)	6.65	(31.88)	24.92
b) Consultancy Services	(6.49)	-	4.19	(7.87)	10.87
Total	(33.91)	(8.62)	10.84	(39.74)	35.79
Less: Interest	-	-	-	-	-
Total Profit before tax	(33.91)	(8.62)	10.84	(39.74)	35.79
Capital employed (Segment assets - segment liabilities)					
Segment assets					
a) Manufacturing and trading of Pharmaceutical drugs	886.24	919.19	1,146.31	886.24	1,146.31
b) Consultancy Services	12.74	12.83	14.04	12.74	14.04
Total Assets	898.98	932.02	1,160.35	898.98	1,160.35
Segment liabilities					
a) Manufacturing and trading of Pharmaceutical drugs	8.55	8.97	8.04	8.55	8.04
b) Consultancy Services	-	-	-	-	-
c) Unallocated liabilities	-	0.37	-	-	-
Total Liabilities	8.55	9.35	8.04	8.55	8.04

2. The Exceptional items represents security written off, which are not recoverable.

3. The above results for the year ended 31st March 2023 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30.05.2023 .

4. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

5. Figures for the last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date unaudited figures upto the third quarter of the respective financial year.

6. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



S M Lal

S M Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 30.05.2023

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd. off: 4th Floor, Plot No. 94, Sagar society, Banjara Hills, Road No. 2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, Mail: info@decipherlabs.in, Ph: 040-48536100

Standalone Statement of Cash Flow for the year ended 31 March 2023.

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Year ended		Year ended	
	31st March, 2023		31st March, 2022	
	(Audited)		(Audited)	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		(263.89)		35.79
Adjustments for :				
Depreciation		5.74		5.01
Loss on sale of asset		7.34		-
Advance to suppliers written off		-		3.05
Balances written back		224.15		(2.14)
Operating Profit before Working Capital Changes		(26.66)		41.71
Adjustments for:				
(Increase) / Decrease in Trade Receivables	8.80		16.83	
(Increase) / Decrease in Inventories	4.42		-	
(Increase) / Decrease in Other Assets	5.28		(4.38)	
Increase / (Decrease) in Trade Payable	-		2.06	
Increase / (Decrease) in Other Liabilities	0.51		(1.44)	
		19.01		13.07
Cash Generated from Operations		(7.65)		54.78
Direct Taxes Paid		-		-
Net Cash generated from/(used in) Operating Activities		(7.65)		54.78
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of Property, Plant & Equipment	8.50		(12.91)	
Investments	-		(25.41)	
Net Cash used in Investing Activities		8.50		(38.32)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from Short Term Borrowings (net)	-		(13.63)	
Net Cash generated from Financing Activities		-		(13.63)
Net decrease in Cash and Cash Equivalents		0.85		2.83
Cash and Cash Equivalents at the beginning of the year		4.76		1.93
Cash and Cash Equivalents at the end of the period		5.62		4.76



For and on behalf of the Board

S M Lal
Director

DIN: 01227151

Place: Hyderabad
Date: 30.05.2023

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Consolidated Statement of Asset and Liabilities as on 31st March,2023

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	As at 31 March 2023 (Audited)	As at 31 March 2022 (Audited)
I. ASSETS		
Non-current Assets		
(a) Property, Plant and Equipment	96.63	33.46
(b) Investment	375.68	26.41
(c) Deferred tax asset (net)	100.69	-
(d) Goodwill	234.82	249.24
(e) Financial assets		
Other financial asset	-	62.62
(f) Other non current assets	0.30	0.30
Current Assets		
(a) Inventories	-	4.42
(b) Financial assets		
(i) Trade receivables	985.43	1,279.21
(ii) Cash and cash equivalents	741.77	1,540.86
(iii) Other Financial Asset	148.99	768.95
(c) Other current assets	132.15	229.42
TOTAL ASSETS	2,816.46	4,194.90
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	1,310.85	1,406.51
Liabilities		
Non-Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	-	667.39
(b) Deferred tax Liabilities (Net)	-	0.14
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	94.94	364.79
(ii) Lease Liability	-	-
(ii) Trade payables		
a) Total outstanding dues of Micro enterprises and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro enterprises and small enterprises	120.14	231.03
(iii) Other Financial liabilities	279.71	381.26
(b) Other current liabilities	0.81	11.05
(c) Current Tax Liabilities (net)	-	122.73
TOTAL EQUITY AND LIABILITIES	2,816.45	4,194.90

For and on behalf of the Board



Sushant Mohan Lal



Director

DIN: 01227151

Place: Hyderabad

Date: 30.05.2023

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd. off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Consolidated Unaudited Financial Results For the Quarter and year ended 31 March 2023

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Year Ended	
	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
	Unaudited	Unaudited	Unaudited	Audited	Audited
I. Revenue from operations	977.51	1,105.60	2,328.77	4,557.27	6,532.24
II. Other income	15.46	(230.78)	16.27	737.06	767.40
III. Total revenue (I + II)	992.97	874.82	2,345.04	5,294.33	7,299.64
IV. Expenses					
Purchase of Stock-in-Trade	10.35	2.25	-	47.25	15.53
Project Management Cost	-	-	719.17	-	719.17
Changes in inventories of finished goods and stock in trade	4.42	-	-	4.42	-
Employee benefits expense	683.99	1,193.75	1,170.94	4,119.12	4,748.68
Finance costs	6.99	12.76	13.90	42.69	47.66
Depreciation and amortisation expense	11.99	10.52	19.84	42.75	86.66
Other expenses	664.63	206.12	176.06	1,229.88	446.34
Total expenses	1,382.37	1,425.40	2,099.91	5,486.11	6,064.04
V. Profit/(Loss) before Exceptional item (III - IV)	(389.40)	(550.58)	245.13	(191.78)	1,235.60
VI. Exceptional items		224.15	-	224.15	-
VII. Profit/(Loss) after Exceptional item (III - IV)	(389.40)	(774.73)	245.13	(415.93)	1,235.60
VIII. Tax expense:					
(1) Current tax	37.52	0.59	50.49	(46.89)	170.44
(2) Deferred tax	(0.03)	(0.03)	(0.24)	(100.81)	(73.97)
(3) Tax of earlier years	-	-	(0.01)	-	0.75
IX. Profit/(Loss) for the period (V-VI)	(426.89)	(775.29)	194.89	(268.23)	1,138.38
X. Other comprehensive income					
Items that will be reclassified to statement of profit and loss	-	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	(16.02)	29.39	35.74	172.57	56.09
XI. Total comprehensive income for the year	(442.91)	(745.90)	230.63	(95.66)	1,194.47
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XI. Earning per equity share					
(1) Basic	(4.23)	(7.68)	1.93	(2.66)	11.27
(2) Diluted	(4.23)	(7.68)	1.93	(2.66)	11.27

Notes

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Year Ended	
	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
	Unaudited	Unaudited	Unaudited	Audited	Audited
Segment Revenue					
a) Manufacturing and Trading of Pharmaceutical drugs	16.80	2.92	38.80	68.82	68.82
b) Consultancy Services	960.71	1,102.67	2,289.97	4,488.45	6,463.42
Total Sales	977.51	1,105.59	2,328.77	4,557.27	6,532.24
Less: Inter Segment Revenue	-	-	-	-	-
Total Revenue from Operations	977.51	1,105.59	2,328.77	4,557.27	6,532.24
Segment Result (Profit Before Tax and Interest from each Segment)					
a) Manufacturing and Trading of Pharmaceutical drugs	2.59	(15.17)	(3.93)	2.72	2.72
b) Consultancy Services	246.64	(746.82)	(761.91)	255.66	255.66
Total	249.23	(761.99)	(765.84)	258.38	258.38
Less: Interest	4.97	12.76	13.90	47.66	47.66
Total Profit before tax	244.26	(774.75)	(779.74)	210.72	210.72
Capital employed (Segment assets - segment liabilities)					
Segment assets					
a) Manufacturing and trading of Pharmaceutical drugs	261.13	78.84	261.13	261.13	261.13
b) Consultancy Services	3,933.17	3,023.67	3,933.17	3,933.17	3,933.17
Total Assets	4,194.30	3,102.51	4,194.30	4,194.30	4,194.30
Segment liabilities					
a) Manufacturing and trading of Pharmaceutical drugs	8.17	8.97	8.17	8.17	8.17
b) Consultancy Services	1,770.21	554.02	1,770.21	1,770.21	1,770.21
Total Liabilities	1,778.38	562.99	1,778.38	1,778.38	1,778.38

2. The Exceptional items represents security deposits written off which are not recoverable.

3. The above results for the Quarter and year ended 31 March 2023 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30.05.2023.

4. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

5. Figures for the last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date unaudited figures upto the third quarter of the respective financial year.

6. The above results as of 31.03.2023 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Barhain.

7. The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

8. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on behalf of the Board

S M Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 30.05.2023

DECIPHER LABS LIMITED. (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Consolidated Cash Flow Statement

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Year Ended 30 March 2023 (Audited)	Year Ended 31 March 2022 (Audited)
Cash flow from operating activities		
Profit before tax	-415.93	1235.60
Adjustments for :		
Exchange differences on translating the financial statements of a foreign operation	172.57	56.09
Depreciation and amortisation expense	42.75	86.66
Finance costs	0.00	47.66
Loss on sale of asset	7.34	0.00
Balances written off	228.57	3.05
PPP loan written off	-722.20	0.00
Bad debts written off	0.00	-727.24
Operating Profit before Working Capital Changes		
Changes in operating assets and liabilities		
(Increase) / Decrease in Trade Receivables	293.79	(401.08)
(Increase) / Decrease in Inventories	-	-
(Increase) / Decrease in Other Assets	555.71	436.38
Increase / (Decrease) in Trade Payable	(110.89)	116.69
Increase / (Decrease) in Other Liabilities	(208.19)	(27.33)
Cash Generated from Operations	(156.48)	826.48
Income taxes paid	-	-
Net cash inflow (outflow) from operating activities	(156.48)	826.48
Cash flows from investing activities		
Purchase of Fixed assets including Capital WIP	(78.30)	(19.92)
Investment in shares	(349.27)	(25.41)
Net cash inflow (outflow) from investing activities	(427.57)	(45.33)
Cash flow from financing activities		
Proceeds/(repayment) of borrowings	(215.04)	237.87
Finance costs	-	(47.66)
Payment for lease liabilities	-	(60.10)
Net cash inflow (outflow) from financing activities	(215.04)	130.10
Net increase (Decrease) in cash and cash equivalents	(799.09)	911.26
Cash and Cash equivalents at the beginning of the Year	1,540.86	697.58
Less: Adjustment on account of cessation of Subsidiary company	-	67.98
Cash and Cash equivalents at the end of the Year	741.77	1,540.86

For and on behalf of the Board



S M Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 30.05.2023



To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai - 400001

Date: 30.05.2023

Dear Sir/ Madam,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, Sushant Mohan Lal, Director of **Decipher Labs Limited** hereby declare that, the statutory Auditors of the company, M/s. Ramanatham & Rao, Chartered Accountants have issued an Audit Report with unmodified/ unqualified opinion on Standalone and Consolidated Audited Financial Results of the company for the quarter and year ended 31st March, 2023.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours sincerely,

For Decipher Labs Limited

Sushant Mohan Lal

DIRECTOR

DIN: 01227151

